1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

  • February 2014
  • -
  • GlobalData
  • -
  • 166 pages

Summary

Table of Contents

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

France’s antipsychotics market will experience significant growth, driven by the introduction of new market entries, expanded access to care, and sociological variables. The German drug market enjoys some of the EU’s highest costs of prescription drugs; however, 90% of Germany’s population receives their medications from state-funded insurances. Latuda, Abilify Maintena, and aripiprazole lauroxil. Disease management in Italy shows a growing acceptance of LAIs into their treatment regimens. LAIs have been growing in popularity in Spain, and the high rate of atypical LAI prescribing over FGA LAIs suggests that prescribers are more comfortable with atypical LAIs. The use of LAIs is quite popular among UK psychiatrists, and the launches of LAI Abilify Maintena and aripiprazole lauroxil during the forecast period are expected to be met with readiness from UK physicians.

Scope

- Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Schizophrenia market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in 5EU.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Schizophrenia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Schizophrenia for the seven majo ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Schizophrenia - Epidemiology Forecast To 2023

Schizophrenia - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Schizophrenia - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Schizophrenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.